Get the Stockscreener App
2.04
0.49%
0.01
Pre-market:
2.04
Compass Therapeutics Inc stock is traded at $2.04, with a volume of 2.17M.
It is up +0.49% in the last 24 hours and up +9.68% over the past month.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
See More
Previous Close:
$2.03
Open:
$2.05
24h Volume:
2.17M
Relative Volume:
0.30
Market Cap:
$367.38M
Revenue:
$850.00K
Net Income/Loss:
$-68.17M
P/E Ratio:
-4.9563
EPS:
-0.4116
Net Cash Flow:
$-53.29M
1W Performance:
+0.99%
1M Performance:
+9.68%
6M Performance:
-59.84%
1Y Performance:
-15.35%
1-Day Range:
$2.02
$2.10
1-Week Range:
$1.88
$2.105
52-Week Range:
$1.61
$6.88
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617-500-8099
Address
80 GUEST STREET, BOSTON
Compare CMPX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
2.04 | 367.38M | 850.00K | -68.17M | -53.29M | -0.4116 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-26 | Initiated | Craig Hallum | Buy |
| Jan-05-26 | Initiated | William Blair | Outperform |
| Dec-03-25 | Initiated | Canaccord Genuity | Buy |
| Dec-03-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Apr-02-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-24-25 | Initiated | Guggenheim | Buy |
| Feb-19-25 | Initiated | Piper Sandler | Overweight |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-15-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-31-23 | Initiated | Jefferies | Buy |
| Jan-27-23 | Initiated | Stifel | Buy |
| May-23-22 | Resumed | H.C. Wainwright | Buy |
| Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
| Jan-19-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Raymond James | Outperform |
| Dec-20-21 | Initiated | SVB Leerink | Outperform |
| Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
Compass Therapeutics eyes FDA path after Tovecimig trial win - MSN
Compass Therapeutics (NASDAQ: CMPX) investors back board, auditor and pay in 2026 votes - Stock Titan
CMPX: Lead oncology asset tovecimig nears FDA filing after strong BTC trial results; multiple catalysts ahead - TradingView
Compass Therapeutics, Inc. (CMPX) Latest Stock News & Headlines - Yahoo Finance
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win - MarketBeat
CMPX News | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
Citizens reiterates Compass Therapeutics stock rating on ASCO data By Investing.com - Investing.com Nigeria
CMPX Stock Chart | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Compass Therapeutics (CMPX) and Tenax Therapeutics (TENX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Emergent Biosolutions (EBS) and Compass Therapeutics (CMPX) - The Globe and Mail
Piper Sandler Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
Stifel reiterates Compass Therapeutics stock rating on ASCO data By Investing.com - Investing.com Canada
Number of shareholders of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
CMPX Q1 2026 Earnings: Narrow EPS Beat Drives Positive Stock ReactionTrough Earnings Signal - thelegaladvocate.com
Compass Therapeutics to Participate in Upcoming June Investor Events - Investing News Network
Biotech Compass Therapeutics to present at Jefferies and Goldman Sachs events - Stock Titan
Compass Therapeutics (CMPX) Breaks Above Support: What’s Driving the 4.6% MoveStrangle Setup - newsline.com
CMPX Q1 2026 Earnings: Narrowed Loss Beats Estimates, Stock Surges 7.25%Forward Guidance Trends - newsline.com
Compass Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Supports Biotech’s Pipeline ProgressNegative Surprise Momentum - newsline.com
Compass Therapeutics reports phase 1 data for CTX-8371 By Investing.com - Investing.com South Africa
Compass Therapeutics reports phase 1 data for CTX-8371 - Investing.com UK
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting - Investing News Network
Compass Therapeutics Announces Promising Phase 1 Results for CTX-8371, Innovative Dual Checkpoint Blocker in Advanced Malignancies - Quiver Quantitative
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc.CMPX - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass ... - Caledonian Record
CMPX: Lead bispecific antibody shows strong efficacy in BTC; FDA submission and pipeline advances ahead - TradingView
Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M - Yahoo Finance
Compass Therapeutics (CMPX) price target decreased by 26.39% to 10.11 - MSN
5 Best NASDAQ Stocks Under $5 to Buy Right Now - Insider Monkey
Compass Therapeutics(CMPX) Stock Options Chain | Quotes & News - Moomoo
Compass Therapeutics’s stock crashes after OS miss in BTC trial - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Thera - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Compass Therapeutics, Inc. (CMPX) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-05-13 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Compass Therapeutics, Inc. (CMPX) And Encourages Shareholders to Reach Out | NDAQ:CMPX | Press Release - Stockhouse
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - FinancialContent
TradingKey - TradingKey
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2026-05-12 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Shareholders to Learn More About the Investigation | NDAQ:CMPX | Press Release - Stockhouse
Compass Therapeutics to Participate in Upcoming May Investor Events - The Manila Times
Compass Therapeutics, Inc. (CMPX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Compass Therapeutics, Inc. (CMPX) Investigation: Bronstein, Gewir - The National Law Review
CMPX (Compass Tx) shares surge 3% as biotech firm essentially meets Q1 loss expectations.Trader Community Insights - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
LifeSci Capital Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Compass Therapeutics Inc Stock (CMPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):